Skip to main content
TipRanks
Go Ultimate75% OFF

InnoCan Pharma (IP40) AI Stock Analysis

6 Followers
DE:IP40

InnoCan Pharma

(Frankfurt:IP40)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Strong Gross MarginsGross margins near 90% indicate favorable product economics and leave substantial revenue available to fund operating expenses, research, and commercialization. If maintained as sales scale, this profitability profile could support improved operating leverage and strengthen the company’s ability to develop its pharmaceutical pipeline.
Negative Factors
Persistent UnprofitabilityThe company remains unprofitable, with negative operating earnings and return on equity, so current operations are not yet generating adequate returns for shareholders. Continued losses can restrict internally funded growth and make successful execution of the product and pharmaceutical strategy more important.

InnoCan Pharma (IP40) vs. iShares MSCI Germany ETF (EWG)

-100%-80%-60%-40%-20%0%20%DE:IP40-86.30%EWG+4.05%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 4.95M
Dividend Yield
―
Average Volume (3M)
679
Price to Earnings (P/E)
-6.2
Beta (1Y)
-0.45
Revenue Growth
-23.91%
EPS Growth
44.31%
Country
Germany
Employees
11
Sector
Consumer Defensive
Sector Strength
62
Industry
Medical - Pharmaceuticals

InnoCan Pharma Business Overview & Revenue Model

Company Description

InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Poland...

InnoCan Pharma Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

DE:IP40 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
TSE:LABSTSE:LABS60NeutralCAD 27.77M-9.23-7.66%―-9.31%66.84%
TSE:AVCNTSE:AVCN58NeutralCAD 12.09M-3.98-65.40%―-3.32%-34.15%
TSE:VMTSE:VM46NeutralCAD 26.17M-6.80-193.11%―360.63%14.21%
TSE:ATLETSE:ATLE42NeutralCAD 39.63M-0.76-2099.75%―-96.13%88.13%

* Consumer Defensive Sector Average

Performance Comparison

-50%0%DE:IP40TSE:ATLETSE:LABSTSE:VMTSE:AVCNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:IP40 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:IP40Innocan Pharma Corporation1.05-8.25-88.66%
TSE:ATLEWillow Biosciences0.08-0.07-46.67%
TSE:LABSMedipharm Labs (Otc)0.06-0.01-15.38%
TSE:VMVoyageur Pharmaceuticals Ltd.0.12-0.03-17.86%
TSE:AVCNAvicanna Inc0.09-0.15-64.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.